Introduction
MYC was initially identified as the target oncogene dysregulated by the t(8;14)(q24;q32) translocation in Burkitt lymphoma (BL). MYC rearrangements involving the heavy and light chain immunoglobulin loci (IG) as well as different non-IG genes were subsequently detected in other lymphoid neoplasms usually associated with very aggressive clinical behavior.
1;2 The transforming oncogenic potential of MYC was initially demonstrated in cell lines and transgenic animal models. 3 However, MYC dysregulation alone does not cause lymphoma, 4 and the t (8;14) has been found at very low levels in blood and bone marrow of healthy individuals, 5 indicating that this genetic alteration per se is not sufficient to trigger For personal use only. on August 16, 2017 . by guest www.bloodjournal.org From
MYC as a transcription factor
MYC is a transcription factor forming heterodimers with the related protein MAX that bind to promoter regions of target genes and modulate their expression by the recruitment of specific co-activators and repressors. [1] [2] [3] Transcriptional activation of MYC is mediated by binding of the histone acetyltransferases CBP/p300, TIP60/GCN5 or the transcription factor P-TEFb, among others. MYC negative cells in the light zone will probably be the subset primed to exit the GC as memory cells or early plasmablasts. BLIMP1 induction in these latter cells will promote the plasma cell differentiation program and will repress MYC expression by binding to its promoter (Fig 1) . 29 The absence of MYC in cells of the GC dark zone is intriguing and raises the question of the mechanisms sustaining the high proliferative program of these cells. Recent gene expression profiling studies of isolated cells from the GC dark and light zones have identified different transcriptional programs. TCF3 (E2A), a potent transcription factor highly expressed in the DZ, 30 upregulates genes required for GC function including CCND3 and E2F2 promoting cell proliferation. 31 Interestingly, TCF3 induces its own negative inhibitor ID3 that is also a target of MYC. 32 These elements may create an autoregulatory loop controlling the transition of cells between the dark and light zones. ID3 expression promoted by TCF3 may contribute to the attenuation of the TCF3 program allowing the cell to move from the dark to the light zone (Fig 2A) . (Table 2 ). In addition, these aggressive lymphomas appear to have acquired additional oncogenic alterations that seem to cooperate with MYC dysregulation by counteracting especially its pro-apoptotic function (Table 2) .
Burkitt lymphoma
Burkitt lymphoma is composed of highly proliferating mature B-cells (Fig 2A) . ID3 mutations (38-68%) are more frequent than those of (Fig 2A) . 31 Reinforcing the relevance of this mechanism, activating mutations of CCND3 have been detected in 38% of sporadic BL and occasional endemic tumors. 31;41 In a recent mouse model, PI3K activation cooperating with MYC induces a lymphoma that resembles human BL, including the acquisition of CCND3 mutations. 4 ID3 and TCF3 mutations have not been identified in DLBCL reinforcing the idea that they are a cooperating mechanism of MYC to develop and maintain the identity of BL.
Diffuse large B-cell lymphoma (DLBCL) with MYC translocations
Approximately 5-14% of DLBCL have been reported to carry MYC translocations.
43;44
MYC amplification, although not systematically studied, has been reported in 2% of DLBCL in a recent study. 45 An amplification of the translocated allele, a phenomenon named complicon, has been observed in some cases. 46 Low copy number gains of MYC are more common in DLBCL (19-38%) and may be associated with higher levels of mRNA expression. 47 The presence of an underlying MYC translocation or amplification cannot be reliably predicted 
Plasmablastic lymphoma and plasma cell myeloma
Plasmablastic lymphoma (PBL) is an aggressive neoplasm composed of a diffuse proliferation of large B cells usually with immunoblastic morphology and the phenotype of a terminally differentiated B-cell characterized by the loss of mature B-cell markers and expression of plasma cell-related antigens (Fig 3C) . 60 EpsteinBarr Virus (EBV) infection with latency I is common but not found in all cases.
These tumors usually present in extranodal sites, and frequently in mucosae of the head and neck region in patients with different immunodeficiency states, mainly HIV infection. [72] [73] [74] MYC translocations are encountered in 41-49% of PBL, virtually all of them with an IG gene as partner and usually in the context of multiple chromosomal aberrations, and seem to confer an inferior prognosis.
73-76
MYC activation also seems to play a role in the progression of plama cell neoplasms particularly from monoclonal gammopathy of undetermined significance (MGUS) to plasma cell myeloma (PCM). This progression is associated with increased levels of MYC expression in the absence of structural alterations of the gene. 77 MYC rearrangements have been found in 0-15% of unselected PCM but in 45% of advanced tumors, particularly in those with extramedullary involvement, and in 65% of PCM cell lines, suggesting that MYC structural alterations are associated with progression of the tumors. 73;78;79 Contrary to PBL, MYC in PCM is frequently rearranged to non-IGH loci. 79 The functional relevance of MYC in PCM has been highlighted by the addiction of these cells to MYC for survival. The terminal B-cell differentiation program is triggered by BLIMP1, a transcription factor highly expressed in PBL. 85 ;86 BLIMP1 represses genes that maintain the mature B-cell identity such as PAX5 and promotes the expression of genes involved in plasma cell differentiation such as XBP1. BLIMP1 also represses MYC and other genes controlling cell proliferation and cell growth. The frequent presence of MYC translocations in these tumors may be required to overcome the repressing effect of BLIMP1 on MYC (Fig 2B) . PCM and probably also related neoplasias have an active unfolded protein response (UPR), a protective antiapoptotic mechanism triggered in the endoplasmic reticulum, that ensures the proper handling of the high protein load produced in these cells. 87 This protective mechanism may help to bypass the pro-apoptotic effect of MYC. Interestingly, MYC oncogenic activation also seems to promote the UPR in transformed cells as a mechanism to escape from its apoptotic effects. (Fig 2B) . Similar to PBL, the activation of MYC by STAT3 may be a mechanism to overcome the repressing effects of BLIMP1.
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Summary and Perspectives
The recent elucidation of the function of MYC in the development of the GC has provided a framework to also better understand its role in lymphomagenesis. 
